For information, the company have advised that the wording of the marketing authorisation for pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma is still to be determined and therefore they have requested a temporary suspension of this appraisal while this issue is resolved. NICE will continue to monitor any development and will update interested parties when the situation changes.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 4044 |
Project Team
| Project lead | Leena Issa |
Email enquiries
- If you have any queries please email TATeam6@nice.org.uk
| External Assessment Group | BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors | Merck Sharpe and Dohme |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Mesothelioma UK |
| Professional groups | Association of Cancer Physicians |
| British Thoracic Oncology Group | |
| British Thoracic Society | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Associated public health groups | None |
| Comparator companies | Aspire Pharma (pemetrexed) (confidentiality agreement not signed, not participating) |
| Bristol Myers Squibb (ipilimumab, nivolumab) (confidentiality agreement signed, participating) | |
| Dr. Reddy’s Laboratories (UK) (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Eli Lilly (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Genus (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Hospira (carboplatin, cisplatin) (confidentiality agreement not signed, not participating) | |
| Pfizer (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Sandoz (cisplatin, pemetrexed) (confidentiality agreement not signed, not participating) | |
| Seacross Pharmaceuticals (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Sun Pharmaceuticals (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Zentiva (pemetrexed) (confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 February 2025 | Suspended. For information, the company have advised that the wording of the marketing authorisation for pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma is still to be determined and therefore they have requested a temporary suspension of this appraisal while this issue is resolved. NICE will continue to monitor any development and will update interested parties when the situation changes. |
| 24 July 2024 | Following a request from the company, the timelines for this appraisal have been revised. The committee meeting will be held on 12 March 2025. |
| 12 June 2024 | Invitation to participate |
| 17 January 2024 - 14 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044 |
| 17 January 2024 - 14 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4044 |
| 17 January 2024 | In progress. Scoping commencing |
For further information on our processes and methods, please see our CHTE processes and methods manual